Clinical Trial Update: Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 gene therapy trial for Leber hereditary optic neuropathy caused by ND1 mutations has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Hereditary Optic Neuropathy

Drugs mentioned

• ND1 gene therapy

Snippet

Sponsor: Neurophth Therapeutics Inc | Conditions: Leber Hereditary Optic Neuropathy (LHON) | Phase 1, Phase 2 | Status: TERMINATED